Sunterra Bio

Sunterra Bio is a clinical-stage biopharmaceutical company based in Carlsbad, California, focused on developing novel inhaled therapies for orphan pulmonary diseases. Founded in 2018, the company leverages specialized formulation and nebulization technologies to deliver targeted treatments directly to the lungs, aiming to improve efficacy and reduce systemic side effects. Its lead candidate, SUN-001, is a small molecule therapeutic currently in Phase 1 clinical trials for the treatment of rare respiratory conditions. Sunterra Bio is an active participant in the respiratory innovation space, frequently engaging with the American Thoracic Society and other industry leaders to advance treatments for high-unmet-need pulmonary disorders.